Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378558 | 1.00 | TAAR1 (0.47) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL22441312 | 1.00 | TAAR1 (0.47) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL7987728 | 0.86 | TAAR1 (0.43) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL11039747 | 0.85 | CA2 (0.42) | KMT2A | |
| SCHEMBL11848566 | 0.83 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL28572268 | 0.83 | TRPA1 (0.44) | MAOAKMT2APTGES2TRPA1 | |
| SCHEMBL492029 | 0.83 | CYP24A1 (0.50) | MEN1KMT2A | |
| SCHEMBL3593823 | 0.83 | NR3C1 (0.44) | TAAR1MEN1KMT2ACYP2D6 | |
| SCHEMBL27467785 | 0.82 | MEN1 (0.48) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL17372882 | 0.81 | MEN1 (0.40) | TAAR1SIGMAR1SLC6A2MAOASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | CMG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11040964-B2 | Compounds and methods of use | Ferro Therapeutics, Inc. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | BRIDGEBIO PHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| EP-1278729-B1 | BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS | GLAXOSMITHKLINE SPA (IT) | 2005-11-09 | — | — | EP | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040029917-A1 | Benzosuberonylpiperdine compounds as analgesics | GLAXOSMITHKLINE S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1278729-A1 | BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS | GlaxoSmithKline S.p.A. (IT) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083454-A1 | BENZOSUBERONYLPIPERIDINE COMPOUNDS AS ANALGESICS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-11-08 | — | — | WO | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | TAAR1 44/4885SIGMAR1 50/4885SLC6A2 2274/4885 |
| US-20220002280-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | TAAR1 4158/4885SIGMAR1 3033/4885SLC6A2 2628/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | TAAR1 634/4885SIGMAR1 2780/4885SLC6A2 269/4885 |
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | IDO1, IDO2, TDO2 | TAAR1 954/4885SIGMAR1 3513/4885SLC6A2 135/4885 |
| US-20200299283-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | TAAR1 4158/4885SIGMAR1 3033/4885SLC6A2 2628/4885 |
| US-20040029917-A1 | Benzosuberonylpiperdine compounds as analgesics | OPRK1, OPRL1, OPRM1 | TAAR1 104/4885SIGMAR1 5/4885SLC6A2 1504/4885 |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | IDO1, IDO2, TDO2 | TAAR1 954/4885SIGMAR1 3513/4885SLC6A2 135/4885 |
| US-11040964-B2 | Compounds and methods of use | AIFM2, GPX4, GPX1 | TAAR1 4158/4885SIGMAR1 3033/4885SLC6A2 2628/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | TAAR1 2444/4885SIGMAR1 197/4885SLC6A2 201/4885 |
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | TAAR1 2013/4885SIGMAR1 804/4885SLC6A2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.